Poolbeg Pharma

Activities: Drug Delivery

Trending Articles

  1. Life sciences sector hit with funding cuts, but novel report highlights feasible industry solutions The review highlights the recent investment reductions observed within the life sciences industry, and why its important to support smaller businesses to develop their innovations
  2. Enhancing sterility: the crucial role of isolators in sterile fill-finish Maintaining the highest levels of sterility is paramount to ensure the safety and efficacy of drugs, with good aseptic manufacturing practices playing a pivotal role in...
  3. Making the most of each cell: single-use perfusion in biopharma processing GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
  4. Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults The results indicate that Medincell's TEV-'749 subcutaneous extended release device for the administration of olanzapine in schizophrenic adults met primary and secondary...
  5. DevPro Biopharma and Bespak complete early studies for novel sustainable albuterol inhaler The novel formulation exhibits a low global warming potential (GWP) and shows comparable performance to Ventolin HFA

Upcoming event

BIO International Convention Digital

3-6 June, 2024 | Convention | San Diego, US See all

Related Content

Finance

Cytokine release syndrome preventative therapy could be a >$10bn market opportunity

Shifting focus to rare and orphan diseases could be beneficial to patient outcomes and company incomes, respectively
Research & Development

Positive outputs from lab-based analysis of RSV drug candidates identified using AI

RSV drug candidates with the highest probability of success prioritised
Manufacturing

Poolbeg Pharma PLC announces directorate change
Regulatory

Immunomodulator II patent granted in Japan for Poolbeg

Further enhancement of the patent portfolio
Ingredients

Poolbeg Pharma to use unique oral delivery platform for new condition

A strategic collaboration has been agreed with a biopharma to focus on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology
Manufacturing

Poolbeg Pharma reveals "significant breakthrough" in influenza AI program

Alongside CytoReason, the analysis has led to the discovery of multiple novel drug targets for the treatment of influenza
Drug Delivery

Poolbeg announces strategic expansion of POLB 001 into oncology

Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications
Subscribe now